Cellectis S.A. Unveils Mid-Year Financial Report
Company Announcements

Cellectis S.A. Unveils Mid-Year Financial Report

Cellectis SA (CLLS) has released an update.

Cellectis S.A., a company operating in the biotechnology sector, has released its unaudited interim condensed consolidated financial statements for the first half of 2024, prepared in accordance with International Accounting Standard 34. The report is presented in U.S. dollars and includes forward-looking statements subject to various risks and uncertainties that could significantly affect actual results. The company emphasizes that these statements are not guarantees of future performance and that outcomes may differ materially due to numerous factors.

For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCellectis S.A. Reports Q3 2024 Financial Results and Updates
TipRanks Auto-Generated NewsdeskCellectis SA Advances CAR T-cell Therapy for Solid Tumors
TheFlyCellectis price target lowered to $5 from $7 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App